Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibitionLeonid Cherkassky(Memorial Sloan Kettering Cancer Center), Prasad S. Adusumilli(Memorial Sloan Kettering Cancer Center)Journal of Clinical InvestigationJuly 24, 201610.1172/jci83092Cited by 1,045SaveCiteExport RISWatch citationsRelated PapersA Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab|Cancer Discovery|2021|551c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation|Nature Cancer|2023|18